DalsnaFinance › Analyst accuracy › Goldman Sachs › INSM target
Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target
with a buy rating and a price target of $188.00, according to a research note released Wednesday.
A fact about what Goldman Sachs published, as reported by Investing.com, not a recommendation from Dalsna Finance; Goldman Sachs is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.